There are concerns about the US offshoring clinical trials to China, with some outlets suggesting this could have negative consequences. The impact of the US-China biotech relationship on the US biopharmaceutical industry and scientists is being discussed. The issue appears to be part of a broader conversation about the US's position in the global biotech industry, although the specifics and potential effects are not entirely clear.